Simultaneous detection of nitrosamines and other sartan-related impurities in active pharmaceutical ingredients by supercritical fluid chromatography

•Simultaneous detection of nitrosamines and monographed impurities in sartans•Novel SFC approach for large group of nitrosamines•High sensitivity and selectivity within extreme short analysis time•Improved reliability and deep understanding by QbD development approach•Both NDMA and NDEA detected in...

Full description

Saved in:
Bibliographic Details
Published inJournal of pharmaceutical and biomedical analysis Vol. 174; pp. 151 - 160
Main Authors Schmidtsdorff, Sebastian, Schmidt, Alexander H.
Format Journal Article
LanguageEnglish
Published England Elsevier B.V 10.09.2019
Subjects
Online AccessGet full text
ISSN0731-7085
1873-264X
1873-264X
DOI10.1016/j.jpba.2019.04.049

Cover

Abstract •Simultaneous detection of nitrosamines and monographed impurities in sartans•Novel SFC approach for large group of nitrosamines•High sensitivity and selectivity within extreme short analysis time•Improved reliability and deep understanding by QbD development approach•Both NDMA and NDEA detected in Losartan API Since July 2018, the pharmacological class of “sartans” has been the subject of considerable media and analytical interest, as it became known that they are contaminated with nitrosamines such as N-nitrosodimethylamine (NDMA), N-nitrosodiethylamine (NDEA) and N-nitrosodiisopropylamine (NDiPA). Previous compendial methods are not able to detect these new contaminants. Using the latest and innovative Quality-by-Design (QbD) approach, it has now been possible to develop an analytical method that enables to investigate sartans, such as valsartan and losartan. Also a large class of different nitrosamines in the ppb range and sartan-related impurities can thus be determined simultaneously in a single analysis using supercritical fluid chromatography (SFC). By using SFC, a broad spectrum of nonpolar and very polar impurities can be separated and analyzed in under 20 min. The analytical method developed is validated for limit testing according to ICH Q2(R1) and fulfills default thresholds of EMA and FDA for testing of drug substances and genotoxic impurities. Additionally, it can also be adapted to other pharmaceuticals that may be contaminated with nitrosamines, since tetrazole synthesis as the underlying cause of nitrosamine contamination is important for a set of other non-sartan drug substances.
AbstractList Since July 2018, the pharmacological class of "sartans" has been the subject of considerable media and analytical interest, as it became known that they are contaminated with nitrosamines such as N-nitrosodimethylamine (NDMA), N-nitrosodiethylamine (NDEA) and N-nitrosodiisopropylamine (NDiPA). Previous compendial methods are not able to detect these new contaminants. Using the latest and innovative Quality-by-Design (QbD) approach, it has now been possible to develop an analytical method that enables to investigate sartans, such as valsartan and losartan. Also a large class of different nitrosamines in the ppb range and sartan-related impurities can thus be determined simultaneously in a single analysis using supercritical fluid chromatography (SFC). By using SFC, a broad spectrum of nonpolar and very polar impurities can be separated and analyzed in under 20 min. The analytical method developed is validated for limit testing according to ICH Q2(R1) and fulfills default thresholds of EMA and FDA for testing of drug substances and genotoxic impurities. Additionally, it can also be adapted to other pharmaceuticals that may be contaminated with nitrosamines, since tetrazole synthesis as the underlying cause of nitrosamine contamination is important for a set of other non-sartan drug substances.
Since July 2018, the pharmacological class of "sartans" has been the subject of considerable media and analytical interest, as it became known that they are contaminated with nitrosamines such as N-nitrosodimethylamine (NDMA), N-nitrosodiethylamine (NDEA) and N-nitrosodiisopropylamine (NDiPA). Previous compendial methods are not able to detect these new contaminants. Using the latest and innovative Quality-by-Design (QbD) approach, it has now been possible to develop an analytical method that enables to investigate sartans, such as valsartan and losartan. Also a large class of different nitrosamines in the ppb range and sartan-related impurities can thus be determined simultaneously in a single analysis using supercritical fluid chromatography (SFC). By using SFC, a broad spectrum of nonpolar and very polar impurities can be separated and analyzed in under 20 min. The analytical method developed is validated for limit testing according to ICH Q2(R1) and fulfills default thresholds of EMA and FDA for testing of drug substances and genotoxic impurities. Additionally, it can also be adapted to other pharmaceuticals that may be contaminated with nitrosamines, since tetrazole synthesis as the underlying cause of nitrosamine contamination is important for a set of other non-sartan drug substances.Since July 2018, the pharmacological class of "sartans" has been the subject of considerable media and analytical interest, as it became known that they are contaminated with nitrosamines such as N-nitrosodimethylamine (NDMA), N-nitrosodiethylamine (NDEA) and N-nitrosodiisopropylamine (NDiPA). Previous compendial methods are not able to detect these new contaminants. Using the latest and innovative Quality-by-Design (QbD) approach, it has now been possible to develop an analytical method that enables to investigate sartans, such as valsartan and losartan. Also a large class of different nitrosamines in the ppb range and sartan-related impurities can thus be determined simultaneously in a single analysis using supercritical fluid chromatography (SFC). By using SFC, a broad spectrum of nonpolar and very polar impurities can be separated and analyzed in under 20 min. The analytical method developed is validated for limit testing according to ICH Q2(R1) and fulfills default thresholds of EMA and FDA for testing of drug substances and genotoxic impurities. Additionally, it can also be adapted to other pharmaceuticals that may be contaminated with nitrosamines, since tetrazole synthesis as the underlying cause of nitrosamine contamination is important for a set of other non-sartan drug substances.
•Simultaneous detection of nitrosamines and monographed impurities in sartans•Novel SFC approach for large group of nitrosamines•High sensitivity and selectivity within extreme short analysis time•Improved reliability and deep understanding by QbD development approach•Both NDMA and NDEA detected in Losartan API Since July 2018, the pharmacological class of “sartans” has been the subject of considerable media and analytical interest, as it became known that they are contaminated with nitrosamines such as N-nitrosodimethylamine (NDMA), N-nitrosodiethylamine (NDEA) and N-nitrosodiisopropylamine (NDiPA). Previous compendial methods are not able to detect these new contaminants. Using the latest and innovative Quality-by-Design (QbD) approach, it has now been possible to develop an analytical method that enables to investigate sartans, such as valsartan and losartan. Also a large class of different nitrosamines in the ppb range and sartan-related impurities can thus be determined simultaneously in a single analysis using supercritical fluid chromatography (SFC). By using SFC, a broad spectrum of nonpolar and very polar impurities can be separated and analyzed in under 20 min. The analytical method developed is validated for limit testing according to ICH Q2(R1) and fulfills default thresholds of EMA and FDA for testing of drug substances and genotoxic impurities. Additionally, it can also be adapted to other pharmaceuticals that may be contaminated with nitrosamines, since tetrazole synthesis as the underlying cause of nitrosamine contamination is important for a set of other non-sartan drug substances.
Author Schmidt, Alexander H.
Schmidtsdorff, Sebastian
Author_xml – sequence: 1
  givenname: Sebastian
  surname: Schmidtsdorff
  fullname: Schmidtsdorff, Sebastian
  email: sebastian.schmidtsdorff@chromicent.de
  organization: Chromicent GmbH, Johann-Hittorf-Str. 8, 12489 Berlin, Germany
– sequence: 2
  givenname: Alexander H.
  surname: Schmidt
  fullname: Schmidt, Alexander H.
  organization: Chromicent GmbH, Johann-Hittorf-Str. 8, 12489 Berlin, Germany
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31174128$$D View this record in MEDLINE/PubMed
BookMark eNp9kU1r3DAQhkVJaTZp_0APRcdevNXIH7KhlxLSDwj00BZ6E2NpnNViW64kB_aH9P9WZtMeeggMSDDPM4f3vWIXs5-Jsdcg9iCgeXfcH5ce91JAtxdVnu4Z20GrykI21c8LthOqhEKJtr5kVzEehRA1dNULdlkCqApku2O_v7lpHRPO5NfILSUyyfmZ-4HPLgUfcXIzRY6z5T4dKPCIIeNFoBETWe6mZQ0uucy4mWO2H4gvBwwTGlqTMzjmxX0g62hOkfcnHteFgtmkbTmMq7PcHIKfMPn7gMvh9JI9H3CM9OrxvWY_Pt5-v_lc3H399OXmw11hyrpJBVjVKCLVVdK2gtpa4YBS2baXZKjsoG3qTghAZeyQP6K3tuks1FBXtgYsr9nb890l-F8rxaQnFw2N4zkPLWUloSnzpYy-eUTXfiKrl-AmDCf9N8oMyDNgcmox0PAPAaG3vvRRb33prS8tqjxdltr_JOMSbg2kgG58Wn1_VikH9OAo6GhyxCYHHXKJ2nr3lP4HiPu1SA
CitedBy_id crossref_primary_10_1002_elps_202000303
crossref_primary_10_1016_j_jpba_2022_115071
crossref_primary_10_1016_j_talanta_2022_124102
crossref_primary_10_1002_jssc_202400277
crossref_primary_10_52711_2231_5675_2023_00005
crossref_primary_10_1002_bmc_6040
crossref_primary_10_1016_j_microc_2022_107341
crossref_primary_10_1021_acs_chemrestox_4c00234
crossref_primary_10_19127_bshealthscience_1377252
crossref_primary_10_22270_jddt_v10i6_s_4444
crossref_primary_10_1016_j_talanta_2020_121659
crossref_primary_10_1016_j_jpba_2021_114458
crossref_primary_10_1002_jssc_202200225
crossref_primary_10_1080_10408398_2020_1803790
crossref_primary_10_1016_j_jpba_2021_113960
crossref_primary_10_1098_rsos_220250
crossref_primary_10_1002_rcm_9432
crossref_primary_10_1002_ardp_202200484
crossref_primary_10_1016_j_xphs_2022_11_029
crossref_primary_10_3390_ijms232012125
crossref_primary_10_1080_10408347_2020_1788375
crossref_primary_10_1016_j_trac_2021_116486
crossref_primary_10_1016_j_xphs_2024_11_003
crossref_primary_10_1080_10408347_2022_2032587
crossref_primary_10_1007_s00216_024_05580_7
crossref_primary_10_22159_ijap_2024v16i5_51376
crossref_primary_10_1002_jssc_202300214
crossref_primary_10_1016_j_aca_2020_07_076
crossref_primary_10_1186_s40543_020_00254_2
crossref_primary_10_1002_dta_3635
crossref_primary_10_1016_j_jpba_2023_115685
crossref_primary_10_1016_j_microc_2020_105594
crossref_primary_10_1016_j_yrtph_2023_105355
crossref_primary_10_1080_10408347_2021_2008226
crossref_primary_10_1016_j_xphs_2023_01_005
crossref_primary_10_1093_jaoacint_qsab100
crossref_primary_10_1016_j_jpba_2020_113460
crossref_primary_10_1016_j_jpbao_2023_100020
crossref_primary_10_1016_j_jchromb_2023_123593
crossref_primary_10_2139_ssrn_4057039
crossref_primary_10_1002_bkcs_12085
crossref_primary_10_46239_ejbcs_1366734
crossref_primary_10_1016_j_cjac_2022_100150
crossref_primary_10_1080_10408347_2023_2253321
crossref_primary_10_1016_j_aca_2021_338568
crossref_primary_10_1016_j_chroma_2023_464416
crossref_primary_10_5937_arhfarm74_49565
crossref_primary_10_1016_j_chroma_2025_465741
Cites_doi 10.1021/es5001352
10.1080/19440049.2010.508184
10.1080/15287394.2018.1460782
10.1016/j.jpba.2015.03.007
10.1016/j.chroma.2012.07.043
10.1016/j.chroma.2018.09.044
10.1016/j.jhazmat.2016.02.048
10.1016/j.jpba.2018.11.010
ContentType Journal Article
Copyright 2019 Elsevier B.V.
Copyright © 2019 Elsevier B.V. All rights reserved.
Copyright_xml – notice: 2019 Elsevier B.V.
– notice: Copyright © 2019 Elsevier B.V. All rights reserved.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.jpba.2019.04.049
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1873-264X
EndPage 160
ExternalDocumentID 31174128
10_1016_j_jpba_2019_04_049
S0731708518328723
Genre Journal Article
GroupedDBID ---
--K
--M
.~1
0R~
1B1
1RT
1~.
1~5
4.4
457
4G.
5GY
5VS
7-5
71M
8P~
9JM
9JN
AABNK
AACTN
AAEDT
AAEDW
AAIAV
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AARLI
AATCM
AAXUO
ABFRF
ABJNI
ABMAC
ABYKQ
ABZDS
ACDAQ
ACGFO
ACGFS
ACIUM
ACRLP
ADBBV
ADECG
ADEZE
AEBSH
AEFWE
AEKER
AENEX
AFKWA
AFTJW
AFXIZ
AFZHZ
AGHFR
AGUBO
AGYEJ
AIEXJ
AIKHN
AITUG
AJOXV
AJSZI
ALCLG
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
AXJTR
BKOJK
BLXMC
C45
CS3
DU5
EBS
EFJIC
EFLBG
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FIRID
FLBIZ
FNPLU
FYGXN
G-Q
GBLVA
IHE
J1W
KOM
M34
M36
M41
MO0
N9A
O-L
O9-
OAUVE
OGGZJ
OVD
OZT
P-8
P-9
P2P
PC.
Q38
RIG
RNS
ROL
RPZ
SCC
SCH
SDF
SDG
SDP
SES
SPC
SPCBC
SSK
SSP
SSZ
T5K
TEORI
YK3
~G-
29L
53G
AAQXK
AATTM
AAXKI
AAYWO
AAYXX
ABFNM
ABWVN
ABXDB
ACLOT
ACNNM
ACRPL
ACVFH
ADCNI
ADMUD
ADNMO
AEIPS
AEUPX
AFJKZ
AFPUW
AGQPQ
AHHHB
AIGII
AIIUN
AJQLL
AKBMS
AKRWK
AKYEP
ANKPU
APXCP
ASPBG
AVWKF
AZFZN
CITATION
EFKBS
FEDTE
FGOYB
G-2
HMT
HMU
HVGLF
HZ~
R2-
SCB
SEW
SPT
WUQ
XPP
~HD
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c356t-1d767ee7942d80e857afa27d8b2ece3918659001a7cdf9000bdd69d15154d51a3
IEDL.DBID .~1
ISSN 0731-7085
1873-264X
IngestDate Sat Sep 27 22:06:43 EDT 2025
Wed Feb 19 02:32:11 EST 2025
Wed Oct 01 02:02:37 EDT 2025
Thu Apr 24 23:07:14 EDT 2025
Fri Feb 23 02:25:41 EST 2024
IsPeerReviewed true
IsScholarly true
Keywords Nitrosamines
Sartans
Quality-by-Design (QbD)
Supercritical fluid chromatography (SFC)
Language English
License Copyright © 2019 Elsevier B.V. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c356t-1d767ee7942d80e857afa27d8b2ece3918659001a7cdf9000bdd69d15154d51a3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 31174128
PQID 2242163391
PQPubID 23479
PageCount 10
ParticipantIDs proquest_miscellaneous_2242163391
pubmed_primary_31174128
crossref_primary_10_1016_j_jpba_2019_04_049
crossref_citationtrail_10_1016_j_jpba_2019_04_049
elsevier_sciencedirect_doi_10_1016_j_jpba_2019_04_049
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2019-09-10
PublicationDateYYYYMMDD 2019-09-10
PublicationDate_xml – month: 09
  year: 2019
  text: 2019-09-10
  day: 10
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Journal of pharmaceutical and biomedical analysis
PublicationTitleAlternate J Pharm Biomed Anal
PublicationYear 2019
Publisher Elsevier B.V
Publisher_xml – name: Elsevier B.V
References Lim, Roh, Kim (bib0100) 2018; 81
U.S. Food & Drug Administration (bib0020) 2018
Hu, Shih, Liu, Chiang, Chen, Chao (bib0120) 2016; 310
World Health Organization (bib0040) 2002
International Agency for Research on Cancer (bib0035) 1978; vol. 17
Schmidtsdorff, Schmidt, Parr (bib0125) 2018; 1577
Sung, Kwak, Park (bib0115) 2010; 27
Venkatesan, Pycke, Halden (bib0110) 2014; 48
European Pharmacopoeia. 9th edition. Strasbourg: Council of Europe.
Guideline, ICH Harmonised Tripartite - Proceedings of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, Geneva, Switzerland.
(bib0095) 2017; vol 2
Barnett, McGregor, Martin (bib0085) 2016; 42
Dispas, Lebrun, Sassiat (bib0075) 2012; 1256
Abdel-Tawab, Gröner, Kopp, Meins, Wübert (bib0025) 2018; 158
Committee for Medicinal Products for Human Use (16. July 2018) CHMP List of questions - To be addressed by the API manufacturers for valsartan-containing medicinal products (Procedure number: EMEA/H/A-31/1471). European Medicines Agency - London, United Kingdom
FDA updates on angiotensin II receptor blocker (ARB) recalls including valsartan, losartan and irbesartan.
Galaon, Cruceru, Petre, Pascu, Iancu, Niculescu (bib0105) 2016; 17
European network of OMCLs (bib0145) 2018
EMA/703416/2018 (bib0030) 2018
.
Buschmann, Holzgrabe (bib0015) 2019; 159
EDQM Knowledge Database (bib0135) 2018
European network of OMCLs (bib0060) 2018
Parr, Joseph (bib0150) 2019; 164
(Last accessed: 01. April 2019).
U.S. Environmental Protection Agency, Federal Facilities Restoration and Reuse Office (bib0045) 2017
RIS.World Online (bib0130) 2018
U.S. Food & Drug Administration (bib0140) 2019
Desfontaine, Guillarme, Francotte, Novakova (bib0065) 2015; 113
U.S. Food & Drug Administration, Center for Drug Evaluation and Research (bib0055) 2018
EMA/526031/2018 (bib0050) 2018
Bartle (bib0070) 1988
EDQM Knowledge Database (10.1016/j.jpba.2019.04.049_bib0135) 2018
World Health Organization (10.1016/j.jpba.2019.04.049_bib0040) 2002
U.S. Food & Drug Administration (10.1016/j.jpba.2019.04.049_bib0020) 2018
European network of OMCLs (10.1016/j.jpba.2019.04.049_bib0145) 2018
Desfontaine (10.1016/j.jpba.2019.04.049_bib0065) 2015; 113
10.1016/j.jpba.2019.04.049_bib0080
U.S. Food & Drug Administration (10.1016/j.jpba.2019.04.049_bib0140) 2019
Schmidtsdorff (10.1016/j.jpba.2019.04.049_bib0125) 2018; 1577
Abdel-Tawab (10.1016/j.jpba.2019.04.049_bib0025) 2018; 158
Lim (10.1016/j.jpba.2019.04.049_bib0100) 2018; 81
U.S. Environmental Protection Agency, Federal Facilities Restoration and Reuse Office (10.1016/j.jpba.2019.04.049_bib0045) 2017
RIS.World Online (10.1016/j.jpba.2019.04.049_bib0130) 2018
10.1016/j.jpba.2019.04.049_bib0010
European network of OMCLs (10.1016/j.jpba.2019.04.049_bib0060) 2018
Buschmann (10.1016/j.jpba.2019.04.049_bib0015) 2019; 159
U.S. Food & Drug Administration, Center for Drug Evaluation and Research (10.1016/j.jpba.2019.04.049_bib0055) 2018
Venkatesan (10.1016/j.jpba.2019.04.049_bib0110) 2014; 48
Galaon (10.1016/j.jpba.2019.04.049_bib0105) 2016; 17
Parr (10.1016/j.jpba.2019.04.049_bib0150) 2019; 164
EMA/526031/2018 (10.1016/j.jpba.2019.04.049_bib0050) 2018
Dispas (10.1016/j.jpba.2019.04.049_bib0075) 2012; 1256
Sung (10.1016/j.jpba.2019.04.049_bib0115) 2010; 27
Barnett (10.1016/j.jpba.2019.04.049_bib0085) 2016; 42
Hu (10.1016/j.jpba.2019.04.049_bib0120) 2016; 310
10.1016/j.jpba.2019.04.049_bib0090
(10.1016/j.jpba.2019.04.049_bib0095) 2017; vol 2
EMA/703416/2018 (10.1016/j.jpba.2019.04.049_bib0030) 2018
International Agency for Research on Cancer (10.1016/j.jpba.2019.04.049_bib0035) 1978; vol. 17
Bartle (10.1016/j.jpba.2019.04.049_bib0070) 1988
10.1016/j.jpba.2019.04.049_bib0005
References_xml – year: 2019
  ident: bib0140
  article-title: Laboratory Analysis of Valsartan Products
– volume: 310
  start-page: 207
  year: 2016
  end-page: 216
  ident: bib0120
  article-title: Elevated urinary levels of carcinogenic N-nitrosamines in patients with urinary tract infections measured by isotope dilution online SPE LC–MS/MS
  publication-title: J. Hazard. Mater.
– reference: (Last accessed: 01. April 2019).
– reference: Committee for Medicinal Products for Human Use (16. July 2018) CHMP List of questions - To be addressed by the API manufacturers for valsartan-containing medicinal products (Procedure number: EMEA/H/A-31/1471). European Medicines Agency - London, United Kingdom
– volume: 159
  start-page: 50
  year: 2019
  end-page: 54
  ident: bib0015
  article-title: Noch mehr Nitrosamine - NDMA, NDEA, NDIPA - wie kommen die Verunreinigungen in die Sartane?
  publication-title: In: Deutsche Apotheker Zeitung
– volume: 17
  start-page: 74
  year: 2016
  end-page: 82
  ident: bib0105
  article-title: New LC-MS/MS method for the determination of eight nitrosamines in drinking water
  publication-title: J Environ Prot Ecol
– volume: 42
  year: 2016
  ident: bib0085
  article-title: Stimuli article: analytical target profile (ATP): structure and application throughout the analytical lifecycle
  publication-title: Pharmacopeial Forum
– volume: 81
  start-page: 465
  year: 2018
  end-page: 480
  ident: bib0100
  article-title: Risk assessment of N-nitrosodiethylamine (NDEA) and N-nitrosodiethanolamine (NDELA) in cosmetics
  publication-title: J Toxicol Environ Health A
– volume: 113
  start-page: 56
  year: 2015
  end-page: 71
  ident: bib0065
  article-title: Supercritical fluid chromatography in pharmaceutical analysis
  publication-title: J. Pharm. Biomed. Anal.
– volume: 164
  start-page: 536
  year: 2019
  end-page: 549
  ident: bib0150
  article-title: NDMA impurity in valsartan and other pharmaceutical products: analytical methods for the determination of N-nitrosamines
  publication-title: J. Pharm. Biomed. Anal.
– year: 2018
  ident: bib0135
  article-title: Valsartan - Monograph Number: 02423. EDQM
– year: 1988
  ident: bib0070
  article-title: Theory and principles of supercritical fluid chromatography
  publication-title: Supercritical Fluid Chromatography
– year: 2018
  ident: bib0060
  article-title: OMCLs Release Three Methods for Determination of NDMA in Sartans
– year: 2018
  ident: bib0055
  article-title: GC/MS Headspace Method for Detection of NDMA in Valsartan Drug Substance
– year: 2018
  ident: bib0145
  article-title: Update on Detection of Nitrosamines in Valsartan and Validated Testing Method
– volume: 158
  start-page: 2898
  year: 2018
  end-page: 2902
  ident: bib0025
  article-title: Valsartan: ZL findet NDMA in Tabletten
  publication-title: Pharm. (1856)
– volume: 48
  start-page: 5085
  year: 2014
  end-page: 5092
  ident: bib0110
  article-title: Detection and occurrence of N-Nitrosamines in archived biosolids from the targeted national sewage sludge survey of the U.S. Environmental protection agency
  publication-title: Environ. Sci. Technol.
– volume: 27
  start-page: 1745
  year: 2010
  end-page: 1754
  ident: bib0115
  article-title: Liquid chromatography-tandem mass spectrometry determination of N-nitrosamines released from rubber or elastomer teats and soothers
  publication-title: Food Addit. Contam. Part A
– volume: vol. 17
  year: 1978
  ident: bib0035
  publication-title: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans - Some N-Nitroso Compounds
– reference: European Pharmacopoeia. 9th edition. Strasbourg: Council of Europe.
– year: 2002
  ident: bib0040
  article-title: N-Nitrosodimethylamine, Concise International Chemical Assessment Document 38
– volume: vol 2
  year: 2017
  ident: bib0095
  publication-title: United States Pharmacopeia and National Formulary (USP 40-NF 35)
– volume: 1256
  start-page: 253
  year: 2012
  end-page: 260
  ident: bib0075
  article-title: Innovative green supercritical fluid chromatography development for the determination of polar compounds
  publication-title: J. Chromatogr. A
– year: 2017
  ident: bib0045
  article-title: Technical Fact Sheet - N-Nitrosodimethylamine
– year: 2018
  ident: bib0050
  article-title: Update on Review of Recalled Valsartan Medicines
– year: 2018
  ident: bib0130
  article-title: Update on the Review of CEP Applications for sartans.EDQM
– reference: .
– year: 2018
  ident: bib0020
  article-title: FDA Provides Update on Its Ongoing Investigation Into Valsartan Products; and Reports on the Finding of an Additional Impurity Identified in One Firm’s Already Recalled Products
– year: 2018
  ident: bib0030
  article-title: EU Authorities Take Further Action in Ongoing Review of Sartans: Zheijiang Huahai Placed Under Increased Supervision; Aurobindo Pharma Stopped From Supplying Irbesartan to the EU
– reference: FDA updates on angiotensin II receptor blocker (ARB) recalls including valsartan, losartan and irbesartan.
– volume: 1577
  start-page: 38
  year: 2018
  end-page: 46
  ident: bib0125
  article-title: Structure assisted impurity profiling for rapid method development in liquid chromatography
  publication-title: J. Chromatogr. A
– reference: Guideline, ICH Harmonised Tripartite - Proceedings of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, Geneva, Switzerland.
– ident: 10.1016/j.jpba.2019.04.049_bib0090
– ident: 10.1016/j.jpba.2019.04.049_bib0080
– year: 2018
  ident: 10.1016/j.jpba.2019.04.049_bib0060
– volume: 159
  start-page: 50
  year: 2019
  ident: 10.1016/j.jpba.2019.04.049_bib0015
  article-title: Noch mehr Nitrosamine - NDMA, NDEA, NDIPA - wie kommen die Verunreinigungen in die Sartane?
  publication-title: In: Deutsche Apotheker Zeitung
– volume: 42
  year: 2016
  ident: 10.1016/j.jpba.2019.04.049_bib0085
  article-title: Stimuli article: analytical target profile (ATP): structure and application throughout the analytical lifecycle
  publication-title: Pharmacopeial Forum
– volume: vol 2
  year: 2017
  ident: 10.1016/j.jpba.2019.04.049_bib0095
– year: 2017
  ident: 10.1016/j.jpba.2019.04.049_bib0045
– volume: 48
  start-page: 5085
  year: 2014
  ident: 10.1016/j.jpba.2019.04.049_bib0110
  article-title: Detection and occurrence of N-Nitrosamines in archived biosolids from the targeted national sewage sludge survey of the U.S. Environmental protection agency
  publication-title: Environ. Sci. Technol.
  doi: 10.1021/es5001352
– volume: 27
  start-page: 1745
  year: 2010
  ident: 10.1016/j.jpba.2019.04.049_bib0115
  article-title: Liquid chromatography-tandem mass spectrometry determination of N-nitrosamines released from rubber or elastomer teats and soothers
  publication-title: Food Addit. Contam. Part A
  doi: 10.1080/19440049.2010.508184
– year: 2018
  ident: 10.1016/j.jpba.2019.04.049_bib0130
– volume: 81
  start-page: 465
  year: 2018
  ident: 10.1016/j.jpba.2019.04.049_bib0100
  article-title: Risk assessment of N-nitrosodiethylamine (NDEA) and N-nitrosodiethanolamine (NDELA) in cosmetics
  publication-title: J Toxicol Environ Health A
  doi: 10.1080/15287394.2018.1460782
– year: 2018
  ident: 10.1016/j.jpba.2019.04.049_bib0050
– year: 2018
  ident: 10.1016/j.jpba.2019.04.049_bib0055
– volume: 113
  start-page: 56
  year: 2015
  ident: 10.1016/j.jpba.2019.04.049_bib0065
  article-title: Supercritical fluid chromatography in pharmaceutical analysis
  publication-title: J. Pharm. Biomed. Anal.
  doi: 10.1016/j.jpba.2015.03.007
– year: 2018
  ident: 10.1016/j.jpba.2019.04.049_bib0145
– ident: 10.1016/j.jpba.2019.04.049_bib0010
– year: 2018
  ident: 10.1016/j.jpba.2019.04.049_bib0135
– year: 1988
  ident: 10.1016/j.jpba.2019.04.049_bib0070
  article-title: Theory and principles of supercritical fluid chromatography
– year: 2018
  ident: 10.1016/j.jpba.2019.04.049_bib0020
– volume: 1256
  start-page: 253
  year: 2012
  ident: 10.1016/j.jpba.2019.04.049_bib0075
  article-title: Innovative green supercritical fluid chromatography development for the determination of polar compounds
  publication-title: J. Chromatogr. A
  doi: 10.1016/j.chroma.2012.07.043
– year: 2019
  ident: 10.1016/j.jpba.2019.04.049_bib0140
– year: 2002
  ident: 10.1016/j.jpba.2019.04.049_bib0040
– ident: 10.1016/j.jpba.2019.04.049_bib0005
– volume: 1577
  start-page: 38
  year: 2018
  ident: 10.1016/j.jpba.2019.04.049_bib0125
  article-title: Structure assisted impurity profiling for rapid method development in liquid chromatography
  publication-title: J. Chromatogr. A
  doi: 10.1016/j.chroma.2018.09.044
– volume: 17
  start-page: 74
  year: 2016
  ident: 10.1016/j.jpba.2019.04.049_bib0105
  article-title: New LC-MS/MS method for the determination of eight nitrosamines in drinking water
  publication-title: J Environ Prot Ecol
– volume: vol. 17
  year: 1978
  ident: 10.1016/j.jpba.2019.04.049_bib0035
– volume: 310
  start-page: 207
  year: 2016
  ident: 10.1016/j.jpba.2019.04.049_bib0120
  article-title: Elevated urinary levels of carcinogenic N-nitrosamines in patients with urinary tract infections measured by isotope dilution online SPE LC–MS/MS
  publication-title: J. Hazard. Mater.
  doi: 10.1016/j.jhazmat.2016.02.048
– volume: 158
  start-page: 2898
  year: 2018
  ident: 10.1016/j.jpba.2019.04.049_bib0025
  article-title: Valsartan: ZL findet NDMA in Tabletten
  publication-title: Pharm. (1856)
– volume: 164
  start-page: 536
  year: 2019
  ident: 10.1016/j.jpba.2019.04.049_bib0150
  article-title: NDMA impurity in valsartan and other pharmaceutical products: analytical methods for the determination of N-nitrosamines
  publication-title: J. Pharm. Biomed. Anal.
  doi: 10.1016/j.jpba.2018.11.010
– year: 2018
  ident: 10.1016/j.jpba.2019.04.049_bib0030
SSID ssj0005194
Score 2.4812894
Snippet •Simultaneous detection of nitrosamines and monographed impurities in sartans•Novel SFC approach for large group of nitrosamines•High sensitivity and...
Since July 2018, the pharmacological class of "sartans" has been the subject of considerable media and analytical interest, as it became known that they are...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 151
SubjectTerms Angiotensin II Type 1 Receptor Blockers - analysis
Chromatography, Supercritical Fluid
Diethylnitrosamine - analysis
Dimethylnitrosamine - analysis
Drug Contamination
Limit of Detection
Losartan - analysis
Nitrosamines
Nitrosamines - analysis
Propylamines - analysis
Quality Control
Quality-by-Design (QbD)
Reference Standards
Risk Assessment
Sartans
Supercritical fluid chromatography (SFC)
Valsartan - analysis
Title Simultaneous detection of nitrosamines and other sartan-related impurities in active pharmaceutical ingredients by supercritical fluid chromatography
URI https://dx.doi.org/10.1016/j.jpba.2019.04.049
https://www.ncbi.nlm.nih.gov/pubmed/31174128
https://www.proquest.com/docview/2242163391
Volume 174
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVESC
  databaseName: Baden-Württemberg Complete Freedom Collection (Elsevier)
  customDbUrl:
  eissn: 1873-264X
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0005194
  issn: 0731-7085
  databaseCode: GBLVA
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVESC
  databaseName: Elsevier SD Freedom Collection
  customDbUrl:
  eissn: 1873-264X
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0005194
  issn: 0731-7085
  databaseCode: .~1
  dateStart: 19950101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVESC
  databaseName: ScienceDirect Freedom Collection 2025
  customDbUrl:
  eissn: 1873-264X
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0005194
  issn: 0731-7085
  databaseCode: ACRLP
  dateStart: 19950101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVESC
  databaseName: ScienceDirect Journal Collection
  customDbUrl:
  eissn: 1873-264X
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0005194
  issn: 0731-7085
  databaseCode: AIKHN
  dateStart: 19950101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVLSH
  databaseName: Elsevier Journals
  customDbUrl:
  mediaType: online
  eissn: 1873-264X
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0005194
  issn: 0731-7085
  databaseCode: AKRWK
  dateStart: 19950101
  isFulltext: true
  providerName: Library Specific Holdings
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NT9wwELUQXHqpCv3alqKpVHEp6caJHSdHhIq2rYSQAImb5cSOCIJstJs97IV_wf_tjOMAlVoOlXJJ4iiWZ2y_Sd68YeyLqmSZuqKOjE1EJOoap5QTMrImd9Y5Zaraq32eZLML8fNSXm6wozEXhmiVYe0f1nS_Wocr0zCa065ppmfonFwRYkCnzFVCip9CKKpi8O3uCc2D-2KI1Dii1iFxZuB4XXclaQ_xwsudkp7m3zenf4FPvwkdv2IvA3qEw6GD22zDtTts_3SQn14fwPljNtXyAPbh9FGYev2a3Z81xB80rcNwH6zrPQ2rhXkNOLGxR-aWSPBgWgs-MQuWOBSmjXzCi7PQ3HZU7A6Da2haMH6phO7q6VdxvIERPNHI-iWUa1iuOreoQj0FqG9WjYXqajFHoBzEst-wi-Pv50ezKJRliKpUZn3ErcoUmrEQic1jl0tlapMom5eJq1xa8DyjUqTcqMrWVJO0tDYrLCEnYSU36Vu22c5b955BbMu4qIyKHeKgWMYlxkuFQUTmMAoUSk4YH-2hq6BZTqUzbvRITrvWZENNNtSxwKOYsK8Pz3SDYsezreVoZv2H32ncUp597vPoExonJP1lGaynE_rJnqU4DhP2bnCWh36kHANARAQf_vOtH9kLOiO-Co932Wa_WLlPCIr6cs97_R7bOvzxa3byG_C9EHQ
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwELVKOcAF8c3yOUioFxo2Tuw4OaKKaoFSVepW6s1yYkdN1Waj3exhL_wL_i8zjtMWCXpAyilxFMsztt_Eb94w9kFVskxdUUfGJiISdY1TygkZWZM765wyVe3VPg-z2Yn4dipPt9jemAtDtMqw9g9rul-tw51pGM1p1zTTY3ROrggxoFPmKknvsLtCJooisE8_b_A8uK-GSK0jah4yZwaS13lXkvgQL7zeKQlq_n13-hf69LvQ_kP2IMBH-Dz08BHbcu1jtnM06E9vdmF-nU612oUdOLpWpt48Yb-OGyIQmtZhvA_W9Z6H1cKiBpzZ2CNzSSx4MK0Fn5kFKxwL00Y-48VZaC47qnaH0TU0LRi_VkJ3dvO3OD7AEJ54ZP0Kyg2s1p1bVqGgAtQX68ZCdbZcIFIOatlP2cn-l_neLAp1GaIqlVkfcasyhXYsRGLz2OVSmdokyuZl4iqXFjzPqBYpN6qyNRUlLa3NCkvQSVjJTfqMbbeL1r1gENsyLiqjYodAKJZxiQFTYRCSOQwDhZITxkd76CqIllPtjAs9stPONdlQkw11LPAqJuzj1TvdINlxa2s5mln_4Xga95Rb33s_-oTGGUnHLIP1dEKn7FmK4zBhzwdnuepHyjECREjw8j-_-o7dm81_HOiDr4ffX7H79ITIKzx-zbb75dq9QYTUl2_9DPgNGfoSCQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Simultaneous+detection+of+nitrosamines+and+other+sartan-related+impurities+in+active+pharmaceutical+ingredients+by+supercritical+fluid+chromatography&rft.jtitle=Journal+of+pharmaceutical+and+biomedical+analysis&rft.au=Schmidtsdorff%2C+Sebastian&rft.au=Schmidt%2C+Alexander+H.&rft.date=2019-09-10&rft.pub=Elsevier+B.V&rft.issn=0731-7085&rft.eissn=1873-264X&rft.volume=174&rft.spage=151&rft.epage=160&rft_id=info:doi/10.1016%2Fj.jpba.2019.04.049&rft.externalDocID=S0731708518328723
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0731-7085&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0731-7085&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0731-7085&client=summon